Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Pancreatic ductal adenocarcinoma impairs HRQoL in senior patients

07 May 2020

Elderly patients of pancreatic ductal adenocarcinoma (PDAC) suffer from worse health-related quality of life (HRQoL), particularly in terms of physical health status, a recent study has found.

Researchers enrolled 128 elderly adults with PDAC (mean age, 76.2±6.4 years; 54.7 percent female) and 512 matched controls (mean age, 76.2±6.4 years; 54.7 percent female) who had no history of cancer. The Short Form 36 (SF-36) and the Veterans-RAND-12 (VR-12) were used to measure HRQoL and the corresponding physical (PCS) and mental (MCS) component summary scores.

Patients and controls were generally comparable in terms of the total number of comorbidities (p=0.4), though cancer patients were more likely to have diabetes (p<0.001), while musculoskeletal diseases were more common in controls (p=0.03).

However, independently of such comorbidities, PDAC patients reported significantly lower mean PCS than healthy controls (29.3±1.2 vs 36.3±0.7; p<0.001). MCS scores were better than PCS, but patients continued to suffer worse HRQoL in this domain than controls (44.8±1.1 vs 49.0±0.7; p<0.001). The resulting adjusted mean differences were 7.0 and 5.1 for PCS and MCS, respectively.

Notably, however, the total number of comorbidities and system-level comorbidities nevertheless appeared to have a negative impact on PCS and MCS in controls.

“The results of this analysis emphasize the need for more attention on the HRQoL of older patients with PDAC,” the researchers said. There have been preliminary investigations regarding possible interventions that may help with this problem, including early supportive care psychotherapy, psychiatric means and symptom management. However, further studies are needed to draw definite conclusions.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.